Your Location:Home > Products > Biochemical Engineering > ABT-199
CasNo: 1257044-40-8
MF: C45H50ClN7O7S
ABT-199, also known as Venetoclax, is a targeted cancer therapy that acts as a selective BCL-2 inhibitor. It is used primarily to treat chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin lymphoma. Venetoclax works by blocking the BCL-2 protein, which is involved in preventing apoptosis (programmed cell death) in cancer cells. By inhibiting this protein, ABT-199 promotes the accumulation of cancer cells and enhances their susceptibility to cell death. It is often used in combination with other therapies to improve treatment outcomes. While generally effective, Venetoclax can have side effects, including neutropenia, anemia, and infections, and its use requires careful monitoring and dose adjustments. Dorne chemical technology co. LTD is a comprehensive chemical enterprise integrating r&d, production and sales. It is a leading manufacturer and supplier of chemical products in China.We develop, produce and market high quality pharmaceuticals, intermediates, specialty chemicals and OLED intermediates, as well as other fine chemicals.Relying on the laboratory and taking the factory as the base, the company has the whole process ability of fine chemical product research and development, production and processing, testing and packaging to export.We have a research team of excellent engineers, professional technical personnel dedicated to the research and development of new products, in addition, we are also committed to industry and academia to provide customized synthetic research services.The company adheres to the quality control and quality assurance system based on ISO standards. QA and QC are applied to the whole process of raw material control, production process control and finished product quality inspection.To provide customers with high quality products and services is our business philosophy !